Landsman, Greg. Thank you, Mr. Chair, and thank you all for being here. I want to talk about biosimilars and get some feedback on how to get some of these really important drugs to market faster. So as you all know, these are generics in Europe. If it's approved, it's approved, and we move forward, or they move for...